DaCapo Brainscience

Executive Summary

DaCapo Brainscience is a private biotechnology company headquartered in Boston, MA, founded in 2016. The company leverages a unique integrated platform combining network biology, analytics for small and sparse data sets, and human induced pluripotent stem cell (iPSC)-derived models that recapitulate neuronal aging and disease progression. This approach aims to identify disease drivers and develop mechanism-linked phenotypic assays for small molecule discovery, with a focus on neurodegenerative diseases such as Alzheimer's and Parkinson's. By using aged neurons in vitro, DaCapo's platform addresses a key limitation of traditional iPSC models, potentially improving translational relevance. The company operates as a private entity with no disclosed pipeline or funding details, suggesting it is at an early stage of development. Its technology has potential for internal drug programs as well as partnerships with larger pharmaceutical companies seeking to leverage its disease modeling and target identification capabilities.

Upcoming Catalysts (preview)

• Q2 2026Announcement of lead optimization or preclinical candidate nomination in a neurodegenerative program40% success
• Q4 2026Pharmaceutical partnership or licensing deal for platform technology35% success
• Q3 2026Disclosure of Series A or B financing round50% success